High-recovery visual identification and single-cell retrieval of circulating tumor cells for genomic analysis using a dual-technology platform integrated with automated immunofluorescence staining.

Autor: Campton DE; RareCyte, Inc, Seattle, WA, USA. dcampton@rarecyte.com., Ramirez AB; RareCyte, Inc, Seattle, WA, USA. aramirez@rarecyte.com., Nordberg JJ; RareCyte, Inc, Seattle, WA, USA. jnordberg@rarecyte.com., Drovetto N; RareCyte, Inc, Seattle, WA, USA. ndrovetto@rarecyte.com., Clein AC; Departments of Laboratory Medicine and Medicine, University of Washington, Washington, USA. aclein@uw.edu., Varshavskaya P; RareCyte, Inc, Seattle, WA, USA. pvarshavskaya@rarecyte.com., Friemel BH; RareCyte, Inc, Seattle, WA, USA. bfriemel@rarecyte.com., Quarre S; RareCyte, Inc, Seattle, WA, USA. squarre@rarecyte.com., Breman A; Medical Genetics Laboratories, Baylor College of Medicine, Houston, USA. breman@bcm.edu., Dorschner M; Department of Pathology, University of Washington, Washington, USA. mod@uw.edu., Blau S; Rainier Hematology-Oncology, Northwest Medical Specialties, Washington, USA. sibelblau@msn.com., Blau CA; Center for Cancer Innovation, University of Washington, Washington, USA. tblau@uw.edu., Sabath DE; Departments of Laboratory Medicine and Medicine, University of Washington, Washington, USA. dsabath@u.washington.edu., Stilwell JL; RareCyte, Inc, Seattle, WA, USA. jstilwell@rarecyte.com., Kaldjian EP; RareCyte, Inc, Seattle, WA, USA. ekaldjian@rarecyte.com.
Jazyk: angličtina
Zdroj: BMC cancer [BMC Cancer] 2015 May 06; Vol. 15, pp. 360. Date of Electronic Publication: 2015 May 06.
DOI: 10.1186/s12885-015-1383-x
Abstrakt: Background: Circulating tumor cells (CTCs) are malignant cells that have migrated from solid cancers into the blood, where they are typically present in rare numbers. There is great interest in using CTCs to monitor response to therapies, to identify clinically actionable biomarkers, and to provide a non-invasive window on the molecular state of a tumor. Here we characterize the performance of the AccuCyte®--CyteFinder® system, a comprehensive, reproducible and highly sensitive platform for collecting, identifying and retrieving individual CTCs from microscopic slides for molecular analysis after automated immunofluorescence staining for epithelial markers.
Methods: All experiments employed a density-based cell separation apparatus (AccuCyte) to separate nucleated cells from the blood and transfer them to microscopic slides. After staining, the slides were imaged using a digital scanning microscope (CyteFinder). Precisely counted model CTCs (mCTCs) from four cancer cell lines were spiked into whole blood to determine recovery rates. Individual mCTCs were removed from slides using a single-cell retrieval device (CytePicker™) for whole genome amplification and subsequent analysis by PCR and Sanger sequencing, whole exome sequencing, or array-based comparative genomic hybridization. Clinical CTCs were evaluated in blood samples from patients with different cancers in comparison with the CellSearch® system.
Results: AccuCyte--CyteFinder presented high-resolution images that allowed identification of mCTCs by morphologic and phenotypic features. Spike-in mCTC recoveries were between 90 and 91%. More than 80% of single-digit spike-in mCTCs were identified and even a single cell in 7.5 mL could be found. Analysis of single SKBR3 mCTCs identified presence of a known TP53 mutation by both PCR and whole exome sequencing, and confirmed the reported karyotype of this cell line. Patient sample CTC counts matched or exceeded CellSearch CTC counts in a small feasibility cohort.
Conclusion: The AccuCyte--CyteFinder system is a comprehensive and sensitive platform for identification and characterization of CTCs that has been applied to the assessment of CTCs in cancer patient samples as well as the isolation of single cells for genomic analysis. It thus enables accurate non-invasive monitoring of CTCs and evolving cancer biology for personalized, molecularly-guided cancer treatment.
Databáze: MEDLINE
Externí odkaz: